[en] In adherent individuals, antiretroviral therapy (ART) suppresses HIV replication, restores immune function, and prevents the development of AIDS. However, ART is not curative and has to be followed lifelong. Persistence of viral reservoirs forms the major obstacle to an HIV cure. HIV latent reservoirs persist primarily by cell longevity and proliferation, but replenishment by residual virus replication despite ART has been proposed as another potential mechanism of HIV persistence. It is a matter of debate whether different ART regimens are equally potent in suppressing HIV replication. Here, we summarized the current knowledge on the role of ART regimens in HIV persistence, focusing on differences in residual plasma viremia and other virological markers of the HIV reservoir between infected individuals treated with combination ART composed of different antiretroviral drug classes.
Disciplines :
Immunology & infectious disease
Author, co-author :
Darcis, Gilles ; Université de Liège - ULiège > I3-Cellular and Molecular Immunology
Berkhout, B.; Laboratory of Experimental Virology, Department of Medical Microbiology, University of Amsterdam, AZ Amsterdam, 1105, Netherlands
Pasternak, A. O.; Laboratory of Experimental Virology, Department of Medical Microbiology, University of Amsterdam, AZ Amsterdam, 1105, Netherlands
Language :
English
Title :
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs
Deeks, S.G.; Lewin, S.R.; Havlir, D.V. The end of AIDS: HIV infection as a chronic disease. Lancet 2013, 382, 1525-1533. [CrossRef]
Sebaaly, J.C.; Kelley, D. Single-Tablet Regimens for the Treatment of HIV-1 Infection. Ann. Pharm. 2017, 51, 332-344. [CrossRef] [PubMed]
Khoury, G.; Darcis, G.; Lee, M.Y.; Bouchat, S.; Van Driessche, B.; Purcell, D.F.J.; Van Lint, C. The Molecular Biology of HIV Latency. Adv. Exp. Med. Biol. 2018, 1075, 187-212. [CrossRef]
Pasternak, A.O.; Berkhout, B. HIV Reservoir: Finding the Right Needles in a Needlestack. Cell Host Microbe 2016, 20, 280-282. [CrossRef]
Darcis, G.; Van Driessche, B.; Van Lint, C. HIV Latency: Should We Shock or Lock? Trends Immunol. 2017, 38, 217-228. [CrossRef]
Dimmock, N.; Easton, A.; Leppard, K.N. Introduction to Modern Virology, 6th ed.; Blackwell Publishing: Malden, MA, USA, 2007.
Fischer, M.; Wong, J.K.; Russenberger, D.; Joos, B.; Opravil, M.; Hirschel, B.; Trkola, A.; Kuster, H.; Weber, R.; Gunthard, H.F. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antivir. Ther. 2002, 7, 91-103.
Pasternak, A.O.; de Bruin, M.; Jurriaans, S.; Bakker, M.; Berkhout, B.; Prins, J.M.; Lukashov, V.V. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J. Infect. Dis. 2012, 206, 1443-1452. [CrossRef]
Pasternak, A.O.; Jurriaans, S.; Bakker, M.; Prins, J.M.; Berkhout, B.; Lukashov, V.V. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLOS ONE 2009, 4, e8490. [CrossRef]
DeMaster, L.K.; Liu, X.H.; VanBelzen, D.J.; Trinite, B.; Zheng, L.J.; Agosto, L.M.; Migueles, S.A.; Connors, M.; Sambucetti, L.; Levy, D.N.; et al. A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. J. Virol. 2016, 90, 2165-2179. [CrossRef]
Baxter, A.E.; Niessl, J.; Fromentin, R.; Richard, J.; Porichis, F.; Charlebois, R.; Massanella, M.; Brassard, N.; Alsahafi, N.; Delgado, G.G.; et al. Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host Microbe 2016, 20, 368-380. [CrossRef]
Sarracino, A.; Gharu, L.; Kula, A.; Pasternak, A.O.; Avettand-Fenoel, V.; Rouzioux, C.; Bardina, M.; De Wit, S.; Benkirane, M.; Berkhout, B.; et al. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3. MBio 2018, 9, e02158-18. [CrossRef]
Yukl, S.A.; Kaiser, P.; Kim, P.; Telwatte, S.; Joshi, S.K.; Vu, M.; Lampiris, H.;Wong, J.K. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci. Transl. Med. 2018, 10, eaap9927. [CrossRef]
Pardons, M.; Baxter, A.E.; Massanella, M.; Pagliuzza, A.; Fromentin, R.; Dufour, C.; Leyre, L.; Routy, J.P.; Kaufmann, D.E.; Chomont, N. Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLOS Pathog. 2019, 15, e1007619. [CrossRef]
Pace, M.J.; Agosto, L.; Graf, E.H.; O'Doherty, U. HIV reservoirs and latency models. Virology 2011, 411, 344-354. [CrossRef]
Pasternak, A.O.; Berkhout, B. What do we measure when we measure cell-associated HIV RNA. Retrovirology 2018, 15, 13. [CrossRef]
Hatano, H.; Jain, V.; Hunt, P.W.; Lee, T.H.; Sinclair, E.; Do, T.D.; Hoh, R.; Martin, J.N.; McCune, J.M.; Hecht, F.; et al. Cell-Based Measures of Viral Persistence Are AssociatedWith Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J. Infect. Dis. 2013, 208, 50-56. [CrossRef] [PubMed]
Imamichi, H.; Dewar, R.L.; Adelsberger, J.W.; Rehm, C.A.; O'Doherty, U.; Paxinos, E.E.; Fauci, A.S.; Lane, H.C. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proc. Natl. Acad. Sci. USA 2016, 113, 8783-8788. [CrossRef]
Baxter, A.E.; O'Doherty, U.; Kaufmann, D.E. Beyond the replication-competent HIV reservoir: Transcription and translation-competent reservoirs. Retrovirology 2018, 15, 18. [CrossRef]
Pollack, R.A.; Jones, R.B.; Pertea, M.; Bruner, K.M.; Martin, A.R.; Thomas, A.S.; Capoferri, A.A.; Beg, S.A.; Huang, S.H.; Karandish, S.; et al. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe 2017, 21, 494-506. [CrossRef]
Avettand-Fènoël, V.; Hocqueloux, L.; Ghosn, J.; Cheret, A.; Frange, P.; Melard, A.; Viard, J.P.; Rouzioux, C. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin. Microbiol. Rev. 2016, 29, 859-880. [CrossRef]
Imamichi, H.; Smith, M.; Adelsberger, J.W.; Izumi, T.; Scrimieri, F.; Sherman, B.T.; Rehm, C.A.; Imamichi, T.; Pau, A.; Catalfamo, M.; et al. Defective HIV-1 proviruses produce viral proteins. Proc. Natl. Acad. Sci. USA 2020, 117, 3704-3710. [CrossRef]
Zicari, S.; Sessa, L.; Cotugno, N.; Ruggiero, A.; Morrocchi, E.; Concato, C.; Rocca, S.; Zangari, P.; Manno, E.C.; Palma, P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses 2019, 11, 200. [CrossRef]
Whitney, J.B.; Hill, A.L.; Sanisetty, S.; Penaloza-MacMaster, P.; Liu, J.; Shetty, M.; Parenteau, L.; Cabral, C.; Shields, J.; Blackmore, S.; et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014, 512, 74-77. [CrossRef]
Colby, D.J.; Trautmann, L.; Pinyakorn, S.; Leyre, L.; Pagliuzza, A.; Kroon, E.; Rolland, M.; Takata, H.; Buranapraditkun, S.; Intasan, J.; et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 2018, 24, 923-926. [CrossRef]
Brodin, J.; Zanini, F.; Thebo, L.; Lanz, C.; Bratt, G.; Neher, R.A.; Albert, J. Establishment and stability of the latent HIV-1 DNA reservoir. Elife 2016, 5, e18889. [CrossRef] [PubMed]
Abrahams, M.R.; Joseph, S.B.; Garrett, N.; Tyers, L.; Moeser, M.; Archin, N.; Council, O.D.; Matten, D.; Zhou, S.; Doolabh, D.; et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 2019, 11, eaaw5589. [CrossRef] [PubMed]
Goonetilleke, N.; Clutton, G.; Swanstrom, R.; Joseph, S.B. Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure. Front. Immunol. 2019, 10, 1966. [CrossRef]
Pankau, M.D.; Reeves, D.B.; Harkins, E.; Ronen, K.; Jaoko,W.; Mandaliya, K.; Graham, S.M.; McClelland, R.S.; Matsen Iv, F.A.; Schiffer, J.T.; et al. Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women. PLoS Pathog. 2020, 16, e1008286. [CrossRef] [PubMed]
Besson, G.J.; Lalama, C.M.; Bosch, R.J.; Gandhi, R.T.; Bedison, M.A.; Aga, E.; Riddler, S.A.; McMahon, D.K.; Hong, F.; Mellors, J.W. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin. Infect. Dis. 2014, 59, 1312-1321. [CrossRef]
Bachmann, N.; von Siebenthal, C.; Vongrad, V.; Turk, T.; Neumann, K.; Beerenwinkel, N.; Bogojeska, J.; Fellay, J.; Roth, V.; Kok, Y.L.; et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat. Commun. 2019, 10, 3193. [CrossRef]
Honeycutt, J.B.; Thayer,W.O.; Baker, C.E.; Ribeiro, R.M.; Lada, S.M.; Cao, Y.; Cleary, R.A.; Hudgens, M.G.; Richman, D.D.; Garcia, J.V. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 2017, 23, 638-643. [CrossRef]
Wallet, C.; De Rovere, M.; Van Assche, J.; Daouad, F.; DeWit, S.; Gautier, V.; Mallon, P.W.G.; Marcello, A.; Van Lint, C.; Rohr, O.; et al. Microglial Cells: The Main HIV-1 Reservoir in the Brain. Front. Cell Infect. Microbiol. 2019, 9, 362. [CrossRef]
Ganor, Y.; Real, F.; Sennepin, A.; Dutertre, C.A.; Prevedel, L.; Xu, L.; Tudor, D.; Charmeteau, B.; Couedel-Courteille, A.; Marion, S.; et al. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. Nat. Microbiol. 2019, 4, 633-644. [CrossRef]
Gras, G.; Kaul, M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 2010, 7, 30. [CrossRef]
Yukl, S.A.; Shergill, A.K.; Ho, T.; Killian, M.; Girling, V.; Epling, L.; Li, P.; Wong, L.K.; Crouch, P.; Deeks, S.G.; et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: Implications for viral persistence. J. Infect. Dis. 2013, 208, 1212-1220. [CrossRef] [PubMed]
Jenabian, M.A.; Costiniuk, C.T.; Mehraj, V.; Ghazawi, F.M.; Fromentin, R.; Brousseau, J.; Brassard, P.; Bélanger, M.; Ancuta, P.; Bendayan, R.; et al. Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. AIDS 2016, 30, 2777-2786. [CrossRef] [PubMed]
Darcis, G.; Coombs, R.W.; Van Lint, C. Exploring the anatomical HIV reservoirs: Role of the testicular tissue. AIDS 2016, 30, 2891-2893. [CrossRef] [PubMed]
Marcelin, A.G.; Tubiana, R.; Lambert-Niclot, S.; Lefebvre, G.; Dominguez, S.; Bonmarchand, M.; Vauthier-Brouzes, D.; Marguet, F.; Mousset-Simeon, N.; Peytavin, G.; et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008, 22, 1677-1679. [CrossRef] [PubMed]
Darcis, G.; Berkhout, B.; Pasternak, A.O. The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like. Front. Immunol. 2019, 10, 2251. [CrossRef] [PubMed]
Doyle, T.; Smith, C.; Vitiello, P.; Cambiano, V.; Johnson, M.; Owen, A.; Phillips, A.N.; Geretti, A.M. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 2012, 54, 724-732. [CrossRef]
Havlir, D.V.; Bassett, R.; Levitan, D.; Gilbert, P.; Tebas, P.; Collier, A.C.; Hirsch, M.S.; Ignacio, C.; Condra, J.; Gunthard, H.F.; et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286, 171-179. [CrossRef]
Palmer, S.;Wiegand, A.P.; Maldarelli, F.; Bazmi, H.; Mican, J.M.; Polis, M.; Dewar, R.L.; Planta, A.; Liu, S.; Metcalf, J.A.; et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 2003, 41, 4531-4536. [CrossRef]
Palmisano, L.; Giuliano, M.; Nicastri, E.; Pirillo, M.F.; Andreotti, M.; Galluzzo, C.M.; Bucciardini, R.; Fragola, V.; Andreoni, M.; Vella, S. Residual viraemia in subjects with chronic HIV infection and viral load 50 copies/mL: The impact of highly active antiretroviral therapy. AIDS 2005, 19, 1843-1847. [CrossRef]
Palmer, S.; Maldarelli, F.; Wiegand, A.; Bernstein, B.; Hanna, G.J.; Brun, S.C.; Kempf, D.J.; Mellors, J.W.; Coffin, J.M.; King, M.S. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 2008, 105, 3879-3884. [CrossRef] [PubMed]
Cillo, A.R.; Vagratian, D.; Bedison, M.A.; Anderson, E.M.; Kearney, M.F.; Fyne, E.; Koontz, D.; Coffin, J.M.; Piatak, M.; Mellors, J.W. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J. Clin. Microbiol. 2014, 52, 3944-3951. [CrossRef] [PubMed]
Tosiano, M.A.; Jacobs, J.L.; Shutt, K.A.; Cyktor, J.C.; Mellors, J.W. A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. J. Clin. Microbiol. 2019, 57, e01714-e01718. [CrossRef] [PubMed]
Shen, L.; Siliciano, R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 2008, 122, 22-28. [CrossRef]
Siliciano, J.D.; Siliciano, R.F. Biomarkers of HIV replication. Curr. Opin. HIV AIDS 2010, 5, 491-497. [CrossRef]
Doyle, T.; Geretti, A.M. Low-level viraemia on HAART: Significance and management. Curr. Opin. Infect. Dis. 2012, 25, 17-25. [CrossRef]
Hilldorfer, B.B.; Cillo, A.R.; Besson, G.J.; Bedison, M.A.; Mellors, J.W. New tools for quantifying HIV-1 reservoirs: Plasma RNA single copy assays and beyond. Curr. HIV AIDS Rep. 2012, 9, 91-100. [CrossRef]
Palmer, S. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy. Curr. Opin. HIV AIDS 2013, 8, 87-92. [CrossRef]
Sahu, G.K. Potential implication of residual viremia in patients on effective antiretroviral therapy. AIDS Res. Hum. Retrovir. 2015, 31, 25-35. [CrossRef]
Sarmati, L.; D'Ettorre, G.; Parisi, S.G.; Andreoni, M. HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Curr. HIV Res. 2015, 13, 250-257. [CrossRef]
Wang, X.Q.; Palmer, S. Single-molecule techniques to quantify and genetically characterise persistent HIV. Retrovirology 2018, 15, 3. [CrossRef] [PubMed]
De Scheerder, M.A.; Vrancken, B.; Dellicour, S.; Schlub, T.; Lee, E.; Shao, W.; Rutsaert, S.; Verhofstede, C.; Kerre, T.; Malfait, T.; et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. Cell Host Microbe 2019, 26, 347-358. [CrossRef]
Chomont, N.; El-Far, M.; Ancuta, P.; Trautmann, L.; Procopio, F.A.; Yassine-Diab, B.; Boucher, G.; Boulassel, M.R.; Ghattas, G.; Brenchley, J.M.; et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009, 15, 893-900. [CrossRef]
Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F.R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A.L.; Mellors, J.W.; Kearney, M.F.; et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014, 345, 179-183. [CrossRef]
Wagner, T.A.; McLaughlin, S.; Garg, K.; Cheung, C.Y.; Larsen, B.B.; Styrchak, S.; Huang, H.C.; Edlefsen, P.T.; Mullins, J.I.; Frenkel, L.M. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014, 345, 570-573. [CrossRef]
Maldarelli, F.; Palmer, S.; King, M.S.; Wiegand, A.; Polis, M.A.; Mican, J.; Kovacs, J.A.; Davey, R.T.; Rock-Kress, D.; Dewar, R.; et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007, 3, e46. [CrossRef]
Martinez-Picado, J.; Deeks, S.G. Persistent HIV-1 replication during antiretroviral therapy. Curr. Opin. HIV AIDS 2016, 11, 417-423. [CrossRef]
Estes, J.D.; Kityo, C.; Ssali, F.; Swainson, L.; Makamdop, K.N.; Del Prete, G.Q.; Deeks, S.G.; Luciw, P.A.; Chipman, J.G.; Beilman, G.J.; et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 2017, 23, 1271-1276. [CrossRef]
Rothenberger, M.; Nganou-Makamdop, K.; Kityo, C.; Ssali, F.; Chipman, J.G.; Beilman, G.J.; Hoskuldsson, T.; Anderson, J.; Jasurda, J.; Schmidt, T.E.; et al. Impact of Integrase Inhibition compared to non-nucleoside inhibition on HIV reservoirs in Lymphoid Tissues. J. Acquir. Immune Defic. Syndr. 2019, 81, 355-360. [CrossRef] [PubMed]
Lorenzo-Redondo, R.; Fryer, H.R.; Bedford, T.; Kim, E.Y.; Archer, J.; Pond, S.L.K.; Chung, Y.S.; Penugonda, S.; Chipman, J.; Fletcher, C.V.; et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016, 530, 51-56. [CrossRef] [PubMed]
Fletcher, C.V.; Staskus, K.; Wietgrefe, S.W.; Rothenberger, M.; Reilly, C.; Chipman, J.G.; Beilman, G.J.; Khoruts, A.; Thorkelson, A.; Schmidt, T.E.; et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 2014, 111, 2307-2312. [CrossRef] [PubMed]
Darcis, G.; Moutschen, M. The effect of treatment simplification on HIV reservoirs. Lancet HIV 2017, 4, e328-e329. [CrossRef]
Di Mascio, M.; Srinivasula, S.; Bhattacharjee, A.; Cheng, L.; Martiniova, L.; Herscovitch, P.; Lertora, J.; Kiesewetter, D. Antiretroviral tissue kinetics: In vivo imaging using positron emission tomography. Antimicrob. Agents Chemother. 2009, 53, 4086-4095. [CrossRef]
Lee, S.A.; Telwatte, S.; Hatano, H.; Kashuba, A.D.M.; Cottrell, M.L.; Hoh, R.; Liegler, T.J.; Stephenson, S.; Somsouk, M.; Hunt, P.W.; et al. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. J. Acquir. Immune Defic. Syndr. 2020, 83, 530-537. [CrossRef]
Kieffer, T.L.; Finucane, M.M.; Nettles, R.E.; Quinn, T.C.; Broman, K.W.; Ray, S.C.; Persaud, D.; Siliciano, R.F. Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 2004, 189, 1452-1465. [CrossRef]
Bailey, J.R.; Sedaghat, A.R.; Kieffer, T.; Brennan, T.; Lee, P.K.;Wind-Rotolo, M.; Haggerty, C.M.; Kamireddi, A.R.; Liu, Y.; Lee, J.; et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 2006, 80, 6441-6457. [CrossRef]
Joos, B.; Fischer, M.; Kuster, H.; Pillai, S.K.; Wong, J.K.; Boni, J.; Hirschel, B.; Weber, R.; Trkola, A.; Gunthard, H.F. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 2008, 105, 16725-16730. [CrossRef]
Evering, T.H.; Mehandru, S.; Racz, P.; Tenner-Racz, K.; Poles, M.A.; Figueroa, A.; Mohri, H.; Markowitz, M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLOS. Pathog. 2012, 8, e1002506. [CrossRef]
Josefsson, L.; von, S.S.; Faria, N.R.; Sinclair, E.; Bacchetti, P.; Killian, M.; Epling, L.; Tan, A.; Ho, T.; Lemey, P.; et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. USA 2013, 110, E4987-E4996. [CrossRef] [PubMed]
Van Zyl, G.U.; Katusiime, M.G.;Wiegand, A.; McManus,W.R.; Bale, M.J.; Halvas, E.K.; Luke, B.; Boltz, V.F.; Spindler, J.; Laughton, B.; et al. No evidence of HIV replication in children on antiretroviral therapy. J. Clin. Investig. 2017, 127, 3827-3834. [CrossRef] [PubMed]
Bozzi, G.; Simonetti, F.R.;Watters, S.A.; Anderson, E.M.; Gouzoulis, M.; Kearney, M.F.; Rote, P.; Lange, C.; Shao, W.; Gorelick, R.; et al. No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. Sci. Adv. 2019, 5, eaav2045. [CrossRef]
van Zyl, G.; Bale, M.J.; Kearney, M.F. HIV evolution and diversity in ART-treated patients. Retrovirology 2018, 15, 14. [CrossRef]
Kearney, M.F.; Wiegand, A.; Shao, W.; McManus, W.R.; Bale, M.J.; Luke, B.; Maldarelli, F.; Mellors, J.W.; Coffin, J.M. Ongoing HIV Replication During ART Reconsidered. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2017; Volume 4.
Rosenbloom, D.I.S.; Hill, A.L.; Laskey, S.B.; Siliciano, R.F. Re-evaluating evolution in the HIV reservoir. Nature 2017, 551, E6-E9. [CrossRef]
Sigal, A.; Kim, J.T.; Balazs, A.B.; Dekel, E.; Mayo, A.; Milo, R.; Baltimore, D. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477, 95-98. [CrossRef]
Pau, A.K.; George, J.M. Antiretroviral therapy: Current drugs. Infect. Dis. Clin. N. Am. 2014, 28, 371-402. [CrossRef]
Dinoso, J.B.; Kim, S.Y.; Wiegand, A.M.; Palmer, S.E.; Gange, S.J.; Cranmer, L.; O'Shea, A.; Callender, M.; Spivak, A.; Brennan, T.; et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 2009, 106, 9403-9408. [CrossRef]
Gandhi, R.T.; Zheng, L.; Bosch, R.J.; Chan, E.S.; Margolis, D.M.; Read, S.; Kallungal, B.; Palmer, S.; Medvik, K.; Lederman, M.M.; et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLOS. Med. 2010, 7, e1000321. [CrossRef]
McMahon, D.; Jones, J.;Wiegand, A.; Gange, S.J.; Kearney, M.; Palmer, S.; McNulty, S.; Metcalf, J.A.; Acosta, E.; Rehm, C.; et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 2010, 50, 912-919. [CrossRef] [PubMed]
Buzon, M.J.; Massanella, M.; Llibre, J.M.; Esteve, A.; Dahl, V.; Puertas, M.C.; Gatell, J.M.; Domingo, P.; Paredes, R.; Sharkey, M.; et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 2010, 16, 460-465. [CrossRef] [PubMed]
Yukl, S.A.; Shergill, A.K.; McQuaid, K.; Gianella, S.; Lampiris, H.; Hare, C.B.; Pandori, M.; Sinclair, E.; Gunthard, H.F.; Fischer, M.; et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010, 24, 2451-2460. [CrossRef] [PubMed]
Hatano, H.; Strain, M.C.; Scherzer, R.; Bacchetti, P.; Wentworth, D.; Hoh, R.; Martin, J.N.; McCune, J.M.; Neaton, J.D.; Tracy, R.P.; et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: A randomized, placebo-controlled trial. J. Infect. Dis. 2013, 208, 1436-1442. [CrossRef]
Hatano, H.; Hayes, T.L.; Dahl, V.; Sinclair, E.; Lee, T.H.; Hoh, R.; Lampiris, H.; Hunt, P.W.; Palmer, S.; McCune, J.M.; et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis. 2011, 203, 960-968. [CrossRef]
Chaillon, A.; Gianella, S.; Lada, S.M.; Perez-Santiago, J.; Jordan, P.; Ignacio, C.; Karris, M.; Richman, D.D.; Mehta, S.R.; Little, S.J.; et al. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J. Virol. 2018, 92, e01589-e01617. [CrossRef]
Rasmussen, T.A.; McMahon, J.H.; Chang, J.J.; Audsley, J.; Rhodes, A.; Tennakoon, S.; Dantanarayana, A.; Spelman, T.; Schmidt, T.; Kent, S.J.; et al. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: A randomised, placebo-controlled, double-blind trial. Lancet HIV 2018, 5, e221-e230. [CrossRef]
Henrich, T.J. Dolutegravir intensification and HIV persistence: 3 + 1 = 3. Lancet HIV 2018, 5, e201-e202. [CrossRef]
Puertas, M.C.; Gómez-Mora, E.; Santos, J.R.; Moltó, J.; Urrea, V.; Morón-López, S.; Hernández-Rodríguez, A.; Marfil, S.; Martínez-Bonet, M.; Matas, L.; et al. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J. Antimicrob. Chemother. 2018, 73, 1940-1948. [CrossRef]
Sharkey, M.; Triques, K.; Kuritzkes, D.R.; Stevenson, M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 2005, 79, 5203-5210. [CrossRef]
Sharkey, M.E.; Teo, I.; Greenough, T.; Sharova, N.; Luzuriaga, K.; Sullivan, J.L.; Bucy, R.P.; Kostrikis, L.G.; Haase, A.; Veryard, C.; et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 2000, 6, 76-81. [CrossRef] [PubMed]
Pierson, T.C.; Kieffer, T.L.; Ruff, C.T.; Buck, C.; Gange, S.J.; Siliciano, R.F. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J. Virol. 2002, 76, 4138-4144. [CrossRef] [PubMed]
Butler, S.L.; Johnson, E.P.; Bushman, F.D. Human immunodeficiency virus cDNA metabolism: Notable stability of two-long terminal repeat circles. J. Virol. 2002, 76, 3739-3747. [CrossRef] [PubMed]
Pace, M.J.; Graf, E.H.; O'Doherty, U. HIV 2-long terminal repeat circular DNA is stable in primary CD4+T Cells. Virology 2013, 441, 18-21. [CrossRef]
Martinez-Picado, J.; Zurakowski, R.; Buzón, M.J.; Stevenson, M. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology 2018, 15, 15. [CrossRef]
Besson, G.J.; McMahon, D.; Maldarelli, F.; Mellors, J.W. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin. Infect. Dis. 2012, 54, 451-453. [CrossRef]
Gandhi, R.T.; Coombs, R.W.; Chan, E.S.; Bosch, R.J.; Zheng, L.; Margolis, D.M.; Read, S.; Kallungal, B.; Chang, M.; Goecker, E.A.; et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2012, 59, 229-235. [CrossRef]
Vallejo, A.; Gutierrez, C.; Hernandez-Novoa, B.; Diaz, L.; Madrid, N.; Abad-Fernandez, M.; Dronda, F.; Perez-Elias,M.J.; Zamora, J.;Muñoz, E.; et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012, 26, 1885-1894. [CrossRef]
Puertas, M.C.; Noguera-Julian, M.; Massanella, M.; Pou, C.; Buzon, M.J.; Clotet, B.; Stevenson, M.; Paredes, R.; Blanco, J.; Martinez-Picado, J. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART. Retrovirology 2016, 13, 51. [CrossRef]
Gutierrez, C.; Diaz, L.; Vallejo, A.; Hernandez-Novoa, B.; Abad, M.; Madrid, N.; Dahl, V.; Rubio, R.; Moreno, A.M.; Dronda, F.; et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: Effect on T cells latently infected. PLOS ONE 2011, 6, e27864. [CrossRef]
Madrid-Elena, N.; García-Bermejo, M.L.; Serrano-Villar, S.; Díaz-de Santiago, A.; Sastre, B.; Gutiérrez, C.; Dronda, F.; Coronel Díaz, M.; Domínguez, E.; López-Huertas, M.R.; et al. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-B Activation in Resting CD4. J. Virol. 2018, 92, e01931-e02017. [CrossRef] [PubMed]
López-Huertas, M.R.; Jiménez-Tormo, L.; Madrid-Elena, N.; Gutiérrez, C.; Rodríguez-Mora, S.; Coiras, M.; Alcamí, J.; Moreno, S. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Sci. Rep. 2017, 7, 2385. [CrossRef] [PubMed]
Cillo, A.R.; Hilldorfer, B.B.; Lalama, C.M.; McKinnon, J.E.; Coombs, R.W.; Tenorio, A.R.; Fox, L.; Gandhi, R.T.; Ribaudo, H.; Currier, J.S.; et al. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS 2015, 29, 2121-2129. [CrossRef] [PubMed]
Puertas, M.C.; Massanella, M.; Llibre, J.M.; Ballestero, M.; Buzon, M.J.; Ouchi, D.; Esteve, A.; Boix, J.; Manzardo, C.; Miró, J.M.; et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014, 28, 325-334. [CrossRef] [PubMed]
Geretti, A.M.; Smith, C.; Haberl, A.; Garcia-Diaz, A.; Nebbia, G.; Johnson, M.; Phillips, A.; Staszewski, S. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir. Ther. 2008, 13, 927-936.
Nicastri, E.; Palmisano, L.; Sarmati, L.; D'Ettorre, G.; Parisi, S.; Andreotti, M.; Buonomini, A.; Pirillo, F.M.; Narciso, P.; Bellagamba, R.; et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (400 HIV-RNA cp/mL) during Different antiretroviral regimens. Curr. HIV Res. 2008, 6, 261-266. [CrossRef]
Riddler, S.A.; Haubrich, R.; DiRienzo, A.G.; Peeples, L.; Powderly, W.G.; Klingman, K.L.; Garren, K.W.; George, T.; Rooney, J.F.; Brizz, B.; et al. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 2008, 358, 2095-2106. [CrossRef]
Bonora, S.; Nicastri, E.; Calcagno, A.; Gonzalez de Requena, D.; D'Ettorre, G.; Sarmati, L.; Palmisano, L.; Vullo, V.; Di Perri, G.; Andreoni, M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation. J. Med. Virol. 2009, 81, 400-405. [CrossRef]
Pozniak, A.; Gupta, R.K.; Pillay, D.; Arribas, J.; Hill, A. Causes and consequences of incomplete HIV RNA suppression in clinical trials. HIV Clin. Trials 2009, 10, 289-298. [CrossRef]
Charpentier, C.; Landman, R.; Laouénan, C.; Joly, V.; Hamet, G.; Damond, F.; Brun-Vézinet, F.; Mentré, F.; Descamps, D.; Yeni, P. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: Associated factors and virological outcome. J. Antimicrob. Chemother. 2012, 67, 2231-2235. [CrossRef]
Gianotti, N.; Galli, L.; Racca, S.; Salpietro, S.; Cossarini, F.; Spagnuolo, V.; Barda, B.; Canducci, F.; Clementi, M.; Lazzarin, A.; et al. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J. Antimicrob. Chemother. 2012, 67, 213-217. [CrossRef] [PubMed]
Maggiolo, F.; Callegaro, A.; Cologni, G.; Bernardini, C.; Velenti, D.; Gregis, G.; Quinzan, G.; Soavi, L.; Iannotti, N.; Malfatto, E.; et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J. Acquir. Immune Defic. Syndr. 2012, 60, 473-482. [CrossRef] [PubMed]
Martin-Blondel, G.; Sauné, K.; Vu Hai, V.; Marchou, B.; Delobel, P.; Izopet, J.; Cuzin, L.; Massip, P. Factors associated with a strictly undetectable viral load in HIV-1-infected patients. HIV Med. 2012, 13, 568-573. [CrossRef] [PubMed]
Parisi, S.G.; Andreis, S.;Mengoli, C.; Scaggiante, R.; Ferretto, R.;Manfrin, V.; Cruciani,M.; Giobbia,M.; Boldrin, C.; Basso, M.; et al. Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. J. Clin. Microbiol. 2012, 50, 258-263. [CrossRef] [PubMed]
Sarmati, L.; Parisi, S.G.; Montano, M.; Andreis, S.; Scaggiante, R.; Galgani, A.; Viscione, M.; Maongelli, G.; Ricciardi, A.; Andreoni, C.; et al. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and-RNA levels and CD4 cell gain. J. Antimicrob. Chemother. 2012, 67, 2932-2938. [CrossRef]
Zheng, L.; Bosch, R.J.; Chan, E.S.; Read, S.; Kearney, M.; Margolis, D.M.; Mellors, J.W.; Eron, J.J.; Gandhi, R.T.; the AIDS Clinical Trials Group (ACTG) A5244 Team. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir. Ther. 2013, 18, 39-43. [CrossRef]
Charpentier, C.; Choquet, M.; Joly, V.; Yeni, P.; Visseaux, B.; Caseris, M.; Brun-Vézinet, F.; Yazdanpanah, Y.; Peytavin, G.; Descamps, D.; et al. Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay. J. Antimicrob. Chemother. 2014, 69, 2819-2825. [CrossRef]
Vancoillie, L.; Demecheleer, E.; Callens, S.; Vogelaers, D.; Vandekerckhove, L.; Mortier, V.; Verhofstede, C. Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. J. Antimicrob. Chemother. 2014, 69, 1098-1103. [CrossRef]
Kiselinova, M.; Geretti, A.M.; Malatinkova, E.; Vervisch, K.; Beloukas, A.; Messiaen, P.; Bonczkowski, P.; Trypsteen, W.; Callens, S.; Verhofstede, C.; et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J. Antimicrob. Chemother. 2015, 70, 3311-3316. [CrossRef]
Konstantopoulos, C.; Ribaudo, H.; Ragland, K.; Bangsberg, D.R.; Li, J.Z. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2015; Volume 2. [CrossRef]
Leierer, G.; Grabmeier-Pfistershammer, K.; Steuer, A.; Geit, M.; Sarcletti, M.; Haas, B.; Kanatschnig, M.; Rappold, M.; Zangerle, R.; Ledergerber, B.; et al. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. PLOS ONE 2015, 10, e0142923. [CrossRef]
McKinnon, E.; Castley, A.; Payne, L.; Pummer, S.; Nolan, D. Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice. HIV Med. 2016, 17, 495-504. [CrossRef] [PubMed]
Riddler, S.A.; Aga, E.; Bosch, R.J.; Bastow, B.; Bedison, M.; Vagratian, D.; Vaida, F.; Eron, J.J.; Gandhi, R.T.; Mellors, J.W.; et al. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J. Infect. Dis. 2016, 213, 556-560. [CrossRef] [PubMed]
Gianotti, N.; Galli, L.; Galizzi, N.; Ripa, M.; Andolina, A.; Nozza, S.; Spagnuolo, V.; Poli, A.; Lazzarin, A.; Castagna, A. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. Int. J. Antimicrob. Agents 2018, 52, 492-499. [CrossRef] [PubMed]
Geretti, A.M.; White, E.; Orkin, C.; Tostevin, A.; Tilston, P.; Chadwick, D.; Leen, C.; Sabin, C.; Dunn, D.T.; UK HIV Drug Resistance Database; et al. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. J. Antimicrob. Chemother. 2019, 74, 746-753. [CrossRef] [PubMed]
Lambert-Niclot, S.; Boyd, A.; Fofana, D.; Valin, N.; Wirden, M.; Meynard, J.L.; Palich, R.; Agher, R.; Valantin, M.A.; Calvez, V.; et al. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2019; Volume 6. [CrossRef]
Darcis, G.; Maes, N.; Pasternak, A.O.; Sauvage, A.S.; Frippiat, F.; Meuris, C.; Uurlings, F.; Lecomte, M.; Léonard, P.; Elmoussaoui, M.; et al. Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy. Antimicrob. Agents Chemother. 2020, 64, e01902-19. [CrossRef]
Jilek, B.L.; Zarr, M.; Sampah, M.E.; Rabi, S.A.; Bullen, C.K.; Lai, J.; Shen, L.; Siliciano, R.F. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 2012, 18, 446-451. [CrossRef]
Shen, L.; Peterson, S.; Sedaghat, A.R.; McMahon, M.A.; Callender, M.; Zhang, H.; Zhou, Y.; Pitt, E.; Anderson, K.S.; Acosta, E.P.; et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 2008, 14, 762-766. [CrossRef]
Yeh, R.F.; Rezk, N.L.; Kashuba, A.D.; Dumond, J.B.; Tappouni, H.L.; Tien, H.C.; Chen, Y.C.; Vourvahis, M.; Horton, A.L.; Fiscus, S.A.; et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob. Agents Chemother. 2009, 53, 2367-2374. [CrossRef]
Maggiolo, F.; Ravasio, L.; Ripamonti, D.; Gregis, G.; Quinzan, G.; Arici, C.; Airoldi, M.; Suter, F. Similar adherence rates favor Different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. 2005, 40, 158-163. [CrossRef]
O'Connor, J.L.; Gardner, E.M.; Mannheimer, S.B.; Lifson, A.R.; Esser, S.; Telzak, E.E.; Phillips, A.N. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J. Infect. Dis. 2013, 208, 40-49. [CrossRef] [PubMed]
Pasternak, A.O.; de Bruin, M.; Bakker, M.; Berkhout, B.; Prins, J.M. High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy. PLoS ONE 2015, 10, e0140791. [CrossRef] [PubMed]
Weiser, S.D.; Guzman, D.; Riley, E.D.; Clark, R.; Bangsberg, D.R. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin. Trials 2004, 5, 278-287. [CrossRef] [PubMed]
Pasternak, A.O.; Kootstra, N.; Vroom, J.; Wit, F.; de Bruin, M.; de Francesco, D.; Sabin, C.; Winston, A.; Prins, J.; Reiss, P.; et al. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors. In Proceedings of the 22nd International AIDS Conference, Amsterdam, Netherlands, 23-27 July 2018.
Trinité, B.; Zhang, H.; Levy, D.N. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal. Retrovirology 2019, 16, 17. [CrossRef] [PubMed]
Jochmans, D.; Anders, M.; Keuleers, I.; Smeulders, L.; Kräusslich, H.G.; Kraus, G.; Müller, B. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology 2010, 7, 89. [CrossRef]
Zerbato, J.M.; Tachedjian, G.; Sluis-Cremer, N. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4. Antimicrob. Agents Chemother. 2017, 61, e01736-e01816. [CrossRef]
Grennan, J.T.; Loutfy, M.R.; Su, D.; Harrigan, P.R.; Cooper, C.; Klein, M.; Machouf, N.; Montaner, J.S.; Rourke, S.; Tsoukas, C.; et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis. J. Infect. Dis. 2012, 205, 1230-1238. [CrossRef]
Sungkanuparph, S.; Overton, E.T.; Seyfried, W.; Groger, R.K.; Fraser, V.J.; Powderly, W.G. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin. Infect. Dis. 2005, 41, 1326-1332. [CrossRef]
Pascom, A.R.; Pinho, R.E.; Rick, F.; Veras, N.M.; Perini, F.B.; Meireles, M.V.; Pereira, G.F.; Benzaken, A.S.; Avelino-Silva, V.I. Comparison of cumulative viraemia following treatment initiation with Different antiretroviral regimens: A real-life study in Brazil. J. Int. AIDS Soc. 2019, 22, e25397. [CrossRef]
Morón-López, S.; Navarro, J.; Jimenez, M.; Rutsaert, S.; Urrea, V.; Puertas, M.C.; Torrella, A.; De Clercq, L.; Ribas, B.P.; Gálvez, C.; et al. Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. Clin. Infect. Dis. 2019, 69, 1320-1328. [CrossRef] [PubMed]
Haïm-Boukobza, S.; Morand-Joubert, L.; Flandre, P.; Valin, N.; Fourati, S.; Sayon, S.; Lavignon, M.; Simon, A.; Girard, P.M.; Katlama, C.; et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mL. AIDS 2011, 25, 341-344. [CrossRef] [PubMed]
Antinori, A.; Perno, C.F.; Giancola, M.L.; Forbici, F.; Ippolito, G.; Hoetelmans, R.M.; Piscitelli, S.C. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 2005, 41, 1787-1793. [CrossRef] [PubMed]
Klatt, N.R.; Chomont, N.; Douek, D.C.; Deeks, S.G. Immune activation and HIV persistence: Implications for curative approaches to HIV infection. Immunol. Rev. 2013, 254, 326-342. [CrossRef]
Hileman, C.O.; Funderburg, N.T. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Curr. HIV AIDS Rep. 2017, 14, 93-100. [CrossRef]
Hileman, C.O.; Kinley, B.; Scharen-Guivel, V.; Melbourne, K.; Szwarcberg, J.; Robinson, J.; Lederman, M.M.; McComsey, G.A. Differential Reduction in Monocyte Activation and Vascular InflammationWith Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. J. Infect. Dis. 2015, 212, 345-354. [CrossRef]
Kelesidis, T.; Moser, C.; Stein, J.H.; Brown, T.T.; Tran, T.T.; Ribaudo, H.J.; Dube, M.P.; Yang, O.O.; Currier, J.S.; McComsey, G.A. Changes in Markers of T-Cell Senescence and ExhaustionWith Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J. Infect. Dis. 2016, 214, 748-752. [CrossRef]
Li, J.Z.; Etemad, B.; Ahmed, H.; Aga, E.; Bosch, R.J.; Mellors, J.W.; Kuritzkes, D.R.; Lederman, M.M.; Para, M.; Gandhi, R.T. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016, 30, 343-353. [CrossRef]
Pasternak, A.O.; Grijsen, M.L.;Wit, F.W.; Bakker, M.; Jurriaans, S.; Prins, J.M.; Berkhout, B. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. JCI Insight 2020, 5, e134196. [CrossRef]
Moreno, S.; Perno, C.F.; Mallon, P.W.; Behrens, G.; Corbeau, P.; Routy, J.P.; Darcis, G. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med. 2019, 20 (Suppl. 4), 2-12. [CrossRef]
Eron, J.; Hung, C.C.; Baril, J.G.; Slim, J.; Falcó, V.; Bogner, J.; Maggiolo, F.; Mills, A.; Sievers, J.; Man, C.Y.; et al. Virologic Response by Baseline Viral LoadWith Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. J. Acquir. Immune Defic. Syndr. 2020, 84, 60-65. [CrossRef]
